HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

Market Cap	241.80B -78.4%
Revenue (ttm)	63.25B +16.8%
Net Income	-7.99B
EPS	-95.29
Shares Out	83.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	521,540
Average Volume	677,105
Open	2,945.00
Previous Close	2,945.00
Day's Range	2,825.00 - 2,945.00
52-Week Range	2,720.00 - 11,090.00
Beta	-0.86
RSI	39.75
Earnings Date	Feb 20, 2026

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 49
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115450

Financial Performance

In 2024, HLB Therapeutics's revenue was 54.93 billion, an increase of 4.45% compared to the previous year's 52.59 billion. Losses were -22.79 billion, 890.1% more than in 2023.